Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months.
Treatment of 16 SLE patients with levamisole resulted in significant reduction of a variety of clinical parameters of the disease. Clinical improvement was both subjective and objective. Thus, levamisole may represent a possible alternative or adjunctive approach to SLE therapy. Although proper assessment of its actual quantitative importance in the treatment of Lupus must await large scale studies under double-blind conditions, nevertheless, these preliminary results are very encouraging.
D000974:Antibodies, Antinuclear; D001402:B-Lymphocytes / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D009017:Morbidity; D009504:Neutrophils; D011241:Prednisone / Q000627:therapeutic use; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000276:immunology*
D000974:Antibodies, Antinuclear; D007978:Levamisole; D011241:Prednisone